MOLECULAR ANALYSIS OF THE T(11--18) MALTOMA BREAKPOINT

T(11--18) Maltoma 断点的分子分析

• 批准号: 2010808
• 负责人: JEFFREY R MORGAN
• 金额: $ 8.1万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-15 至 2002-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2010808
• 关键词: chromosome translocation; genetic mapping; genetically modified animals; human tissue; in situ hybridization; laboratory mouse; molecular cloning; molecular oncology; molecular pathology; neoplasm /cancer genetics; nonHodgkin's lymphoma; northern blottings; nucleic acid sequence; secretory immune system

DESCRIPTION (Applicant's Description): The candidate, Dr. Jeffrey Morgan, is now completing training in Hematology-Oncology at Brigham and Women's Hospital and will be promoted to Instructor in Medicine beginning in July, 1996. He is committed to a career in academic medicine, with an emphasis in basic cancer research. He has previously worked in the laboratories of Dr. Eric Kandel and Dr. David Livingston. In the laboratory of his mentor, Dr. Jeffrey Sklar, Chief of the Division of Molecular Oncology in the Department of Pathology, he is now developing the skills necessary to establish himself as an independent investigator. The Sklar laboratory offers an intellectually vital and scientifically diverse environment. Projects include genomic cloning techniques, mutation screening, minimal residual disease detection, somatic hypermutation and a functional analysis of Notch, a signal transducer cloned in the lab, implicated in human T cell lymphoma. In this setting, the extensive intellectual, clinical and laboratory resources of the BWH Pathology Department are accessible to Dr. Morgan. Outside the laboratory and the Department, the Harvard Medical School and Harvard Medical Area offer a wealth of educational opportunities. Courses in immunology and genetics will be undertaken in Years 01 and 02 of this RCA; Years 03 to 05 will see a further intensification of the research experience. In the laboratory, he will focus on the molecular pathogenesis of MALT lymphoma. The t(11;18)(q21;q21) is characteristic of this disease. In preliminary studies, he has identified YACs flanking and spanning this breakpoint. Positional cloning will be used to identify the translocation-associated gene products. Expression of these gene products will be correlated with tumor stage. Finally, models will be developed to facilitate functional analysis.

描述（申请人描述）： 候选人杰弗里·摩根博士现在正在完成 布莱根妇女医院血液肿瘤科，并将晋升为 1996年7月开始担任医学讲师。 他致力于一项事业 学术医学，重点是基础癌症研究。 他 之前在Eric Kandel博士和大卫博士的实验室工作 利文斯顿。 在他的导师、首席执行官杰弗里·斯克拉博士的实验室里 病理学系分子肿瘤科，他现在是 发展必要的技能，以建立自己作为一个独立的 调查员 Sklar实验室提供了一个智力上至关重要和科学上 多样的环境。 项目包括基因组克隆技术、突变 筛查、微小残留病检测、体细胞超突变和 实验室克隆的信号转换器Notch的功能分析， 与人类T细胞淋巴瘤有关 在这种情况下，广泛的 BWH病理学的知识、临床和实验室资源 摩根医生可以进入这个部门。 在实验室外， 系，哈佛医学院和哈佛医学区提供了一个 丰富的教育机会。 免疫学和遗传学课程 将在本RCA的01年和02年进行; 03年至05年将看到 进一步强化研究经验。 在实验室，他将专注于MALT的分子发病机制 淋巴瘤 t（11;18）（q21;q21）是本病的特征性表现。 在 初步研究，他已经确定了YAC侧翼和跨越这一点， 断点。 将使用定位克隆来鉴定 易位相关基因产物。 这些基因产物的表达 将与肿瘤分期相关。 最后，将开发模型， 便于功能分析。